Literature DB >> 15177498

Actin-dependent tumour cell adhesion after short-term exposure to the antimetastasis ruthenium complex NAMI-A.

G Sava1, F Frausin, M Cocchietto, F Vita, E Podda, P Spessotto, A Furlani, V Scarcia, G Zabucchi.   

Abstract

Imidazolium trans-imidazoledimethylsulphoxidetrachlororuthenate (NAMI-A) was tested in vitro on the pro-adhesive properties, evaluated as resistance to trypsin treatment, which is a bona fide measure of adhesion strength, of KB and HeLa carcinoma cell lines and on human polymorphonuclear neutrophils (HPMN). NAMI-A increased the pro-adhesive activity of KB cells at 0.001 mM concentration, after few minutes incubation and this effect was not influenced by the vehicle used for cell challenge, neither did it depend on NAMI-A concentration or on temperature. The same effect occurred on HeLa cells at 0.01 mM NAMI-A. This effect, detected at concentrations up to 100 times lower than those necessary to block cells at the G(2)-M premitotic phase of cell cycle, or to inhibit matrix metalloproteinase release or cell invasion, was not related to ruthenium uptake by tumour cells. HeLa cells and healthy HPMN, following short exposure to 0.1 mM NAMI-A, assumed a different shape, with the extrusion of filopodia (HeLa) and of large lamellopodia (HPMN), which increased their interactions with the substrate. This effect was attributed to stabilisation, altered turnover and sensitivity to cytochalasin D of actin filaments. Provided that adhesion is associated with cell motility and invasion, these data suggest that NAMI-A may exert antimetastatic properties at concentrations lower than those observed in the lungs at the end of a conventional intraperitoneal treatment in vivo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15177498     DOI: 10.1016/j.ejca.2004.01.034

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  9 in total

1.  Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy.

Authors:  Suzanne Leijen; Sjaak A Burgers; Paul Baas; Dick Pluim; Matthijs Tibben; Erik van Werkhoven; Enzo Alessio; Gianni Sava; Jos H Beijnen; Jan H M Schellens
Journal:  Invest New Drugs       Date:  2014-10-25       Impact factor: 3.850

2.  Cancer-specific mutations in p53 induce the translation of Δ160p53 promoting tumorigenesis.

Authors:  Marco M Candeias; Masatoshi Hagiwara; Michiyuki Matsuda
Journal:  EMBO Rep       Date:  2016-10-04       Impact factor: 8.807

3.  Effects of the ruthenium-based drug NAMI-A on the roles played by TGF-β1 in the metastatic process.

Authors:  L Brescacin; A Masi; G Sava; A Bergamo
Journal:  J Biol Inorg Chem       Date:  2015-09-14       Impact factor: 3.358

4.  Kinetics and mechanism of the reduction of (ImH)[trans-RuCl4(dmso)(Im)] by ascorbic acid in acidic aqueous solution.

Authors:  Malgorzata Brindell; Dorota Piotrowska; Azza A Shoukry; Grazyna Stochel; Rudi van Eldik
Journal:  J Biol Inorg Chem       Date:  2007-05-15       Impact factor: 3.358

Review 5.  Metallo-Drugs in Cancer Therapy: Past, Present and Future.

Authors:  Roxana Liana Lucaciu; Adriana Corina Hangan; Bogdan Sevastre; Luminița Simona Oprean
Journal:  Molecules       Date:  2022-10-01       Impact factor: 4.927

6.  Inhibitory Effects of the Ruthenium Complex KP1019 in Models of Mammary Cancer Cell Migration and Invasion.

Authors:  A Bergamo; A Masi; M A Jakupec; B K Keppler; G Sava
Journal:  Met Based Drugs       Date:  2009-09-17

7.  Cytotoxicity and anti-tumor effects of new ruthenium complexes on triple negative breast cancer cells.

Authors:  Cecília P Popolin; João P B Reis; Amanda B Becceneri; Angélica E Graminha; Márcio A P Almeida; Rodrigo S Corrêa; Legna A Colina-Vegas; Javier Ellena; Alzir A Batista; Márcia R Cominetti
Journal:  PLoS One       Date:  2017-09-12       Impact factor: 3.240

Review 8.  Fighting Cancer with Transition Metal Complexes: From Naked DNA to Protein and Chromatin Targeting Strategies.

Authors:  Giulia Palermo; Alessandra Magistrato; Tina Riedel; Thibaud von Erlach; Curt A Davey; Paul J Dyson; Ursula Rothlisberger
Journal:  ChemMedChem       Date:  2015-12-04       Impact factor: 3.466

Review 9.  Recent developments in the nanostructured materials functionalized with ruthenium complexes for targeted drug delivery to tumors.

Authors:  Prakash Thangavel; Buddolla Viswanath; Sanghyo Kim
Journal:  Int J Nanomedicine       Date:  2017-04-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.